Prevalence of prostate cancer clinical states and mortality in the United States: Estimates using a dynamic progression model

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Scher, Howard I ^a   Solo, Kirk ^b   Valant, Jason ^b   Todd, Mary B ^c   Mehra, Maneesha ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Lexidyne LLC   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; DOCETAXEL; TESTOSTERONE;

ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); METASTASIS; METASTASIS POTENTIAL; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION RESEARCH; PREVALENCE; PRIMARY TUMOR; RISK ASSESSMENT; SIMULATION; STATISTICAL MODEL; TESTOSTERONE BLOOD LEVEL; UNITED STATES; BIOLOGICAL MODEL; EPIDEMIOLOGY; INCIDENCE; META ANALYSIS; MORTALITY; PROSTATE TUMOR;

CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; INCIDENCE; MALE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 84949057888     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0139440     Document Type: Article

References (28)

1. American Cancer Society. Cancer Facts & Figures 2014. Atlanta: American Cancer Society; 2014.
2. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, et al. NCCN clinical guidelines in oncology-prostate cancer. Version I.2015. National Comprehensive Cancer Network Web site. Available: http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf.
3. Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008; 19(2): 175-81. PMID: 18027095
4. Scher HI, Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology. 2000; 55(3): 323-7. PMID: 10699601
5. Solo K, Mehra M, Dhawan R, Valant J, Scher HI. Prevalence of prostate cancer (PC) clinical states (CS) in the United States: estimates using a dynamic progression model. J Clin Oncol. 2011; 29 (Suppl). Abstract 4637.
6. Scher HI, Morris MJ, Basch E, Heller G. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol. 2011; 29(27): 3695-704. doi: 10.1200/JCO. 2011.35.8648 PMID: 21859988
7. U.S. National Institutes of Health. Surveillance Epidemiology and End Results. National Cancer Institute website. Available: http://seer.cancer.gov/.
8. Yossepowitch O, Eggener SE, Bianco FJ Jr, Carver BS, Serio A, Scardino PT, et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol. 2007; 178(2): 493-9. PMID: 17561152
9. Antonarakis ES, Blackford AL, Garrett-Mayer E, Eisenberger MA. Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review. J Clin Oncol. 2007; 25 (31): 4998-5008. PMID: 17971600
10. Bill-Axelson A, Holmberg L, Filen F, Ruutu M, Garmo H, Busch C, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008; 100(16): 1144-54. doi: 10.1093/jnci/djn255 PMID: 18695132
11. Moreira DM, Presti JC Jr., Aronson WJ, Terris MK, Kane CJ, Amling CL, et al. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. J Urol. 2009; 182(5): 2250-5. doi: 10.1016/j.juro.2009.07.022 PMID: 19758614
12. D'Amico AV, Hui-Chen M, Renshaw AA, Sussman B, Roehl KA, Catalona WJ. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. J Urol. 2006; 176(6 Pt 2): S11-5. PMID: 17084157
13. Shappley WV III, Kenfield SA, Kasperzyk JL, Qiu W, Stampfer MJ, Sanda MG, et al. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol. 2009; 27(30): 4980-5. doi: 10.1200/JCO.2008.21.2613 PMID: 19720918
14. Bolla M, van PH, Collette L, van CP, Vekemans K, Da PL, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005; 366(9485): 572-8. PMID: 16099293
15. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002; 360(9327): 103-6. PMID: 12126818
16. Antonarakis ES, Chen Y, Elsamanoudi SI, Brassell SA, Da Rocha MV, Eisenberger MA, et al. Longterm overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. BJU Int. 2011; 108(3): 378-85. doi: 10.1111/j.1464-410X.2010.09878.x PMID: 21091976
17. Smith MR, Cook R, Lee KA, Nelson JB. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer. 2011; 117(10): 2077-85. doi: 10.1002/cncr.25762 PMID: 21523719
18. Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G, et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol. 2012; 188(4): 1164-9. doi: 10.1016/j.juro.2012.06.046 PMID: 22921015
19. Noguchi M, Noda S, Yoshida M, Ueda S, Shiraishi T, Itoh K. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol. 2004; 11(2): 103-9. PMID: 14706014
20. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24(19): 3089-94. PMID: 16809734
21. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351(15): 1513-20. PMID: 15470214
22. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364(21): 1995-2005. doi: 10.1056/ NEJMoa1014618 PMID: 21612468
23. Oudard S, Banu E, Medioni J, Scotte F, Banu A, Levy E, et al. What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel? BJU Int. 2009; 103(12): 1641-6. doi: 10.1111/j.1464-410X.2008.08283.x PMID: 19210673
24. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011; 103(2): 117-28. doi: 10.1093/jnci/djq495 PMID: 21228314
25. American Cancer Society. Cancer facts & figures 2009. American Cancer Society website. Available: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2009/index.
26. Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. National Vital Statistics Reports. Centers for Disease Control and Prevention Web site. Available: http://stacks.cdc.gov/view/cdc/21508.
27. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26(7): 1148-59. doi: 10.1200/JCO.2007.12.4487 PMID: 18309951
28. Schroder FH, Hugosson J, Carlsson S, Tammela T, Maattanen L, Auvinen A, et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol. 2012; 62(5): 745-752.PMID: 22704366